1	State of Arkansas As Engrossed: H3/4/21 H3/15/21 93rd General Assembly A Bill	
2		0
3	Regular Session, 2021HOUSE BILL 1569	9
4	Dry Democratetives Lyndsterm Device Devid Deces Drever C. Cooper Evens Evens D. Comer	
5	By: Representatives Lundstrum, Barker, Boyd, Bragg, Brown, C. Cooper, Evans, Furman, D. Garner,	
6	Gazaway, Haak, Hawks, Lowery, Maddox, Murdock, Penzo, Pilkington, Ray, Scott, S. Smith, Watson, D).
7	Whitaker, Wing, Wooten, C. Fite, V. Flowers, McCullough, Rye	
8	By: Senators Rapert, L. Chesterfield, Gilmore, M. Johnson, Teague, T. Garner	
9 10	For An Act To Be Entitled	
11	AN ACT TO ESTABLISH THE ARKANSAS FAIRNESS IN COST	
12	SHARING ACT; AND FOR OTHER PURPOSES.	
13		
14		
15	Subtitle	
16	TO ESTABLISH THE ARKANSAS FAIRNESS IN	
17	COST SHARING ACT.	
18		
19		
20	BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:	
21		
22	SECTION 1. TEMPORARY LANGUAGE. DO NOT CODIFY. Legislative findings	
23	and intent.	
24	(a) The General Assembly finds that:	
25	(1) Arkansans frequently rely on state-regulated commercial	
26	insurers to secure access to the prescription drugs needed to protect their	
27	health;	
28	(2) Commercial insurance designs increasingly require a patient	
29	to bear significant out-of-pocket costs for the patient's prescription drugs;	-
30	(3) High out-of-pocket costs on prescription drugs affect the	
31	ability of patients to start new and necessary prescription drugs and to	
32	adhere to their current prescription drugs regimen;	
33	(4) High or unpredictable cost-sharing requirements are a main	
34	driver of elevated out-of-pocket costs for patients and allow insurers to	
35	capture and divert rebates, discounts, and price concessions that are	
36	intended to benefit patients at the pharmacy counter;	



.

1	(5) Insurers unfairly increase cost-sharing burdens on patients
2	by refusing to count third-party assistance toward a patient's cost-sharing
3	contributions;
4	(6) The burdens of high or unpredictable cost-sharing
5	requirements are borne disproportionately by patients with chronic or
6	debilitating medical conditions;
7	(7) It is necessary to restrict the ability of insurers and
8	their intermediaries to use unfair cost-sharing design to retain rebates,
9	discounts, and price concessions that instead should be directly passed on to
10	patients as cost savings at the point of sale of prescription drugs; and
11	(8) Patients need equitable and accessible health coverage that
12	does not impose unfair cost-sharing burdens upon them.
13	(b) It is the intent of the General Assembly to ensure that a state-
14	regulated insurer and the entities that contract with the state-regulated
15	insurer do not restrict patient access to prescription drugs by refusing to
16	count third-party cost-sharing assistance toward a patient's cost-sharing
17	obligations, a practice that is detrimental to the consumer.
18	
19	SECTION 2. Arkansas Code Title 23, Chapter 79, is amended to add an
20	additional subchapter to read as follows:
21	<u>Subchapter 21 — Arkansas Fairness in Cost Sharing Act</u>
22	
23	23-79-2101. Title.
24	This subchapter shall be known and may be cited as the "Arkansas
25	Fairness in Cost Sharing Act".
26	
27	<u>23-79-2102. Definitions.</u>
28	As used in this subchapter:
29	(1) "Cost-sharing requirement" means a copayment, coinsurance,
30	deductible, or annual limitation on cost sharing, including without
31	limitation a limitation subject to the Patient Protection and Affordable Care
32	Act, Pub. L. No. 111-148, that is required by or on behalf of an enrollee in
33	order to receive a specific healthcare service, including a prescription
34	drug, covered by a health benefit plan;
35	(2) "Enrollee" means an individual entitled to healthcare
36	services from a healthcare insurer;

03-15-2021 10:17:43 ANS138

1	(3)(A) "Health benefit plan" means any individual, blanket, or
2	group plan, policy, or contract for healthcare services issued or delivered
3	by a healthcare insurer in this state.
4	(B) "Health benefit plan" does not include:
5	(i) Accident-only plans;
6	(ii) Specified disease plans;
7	(iii) Disability income plans;
8	(iv) Plans that provide only for indemnity for
9	hospital confinement;
10	(v) Long-term-care-only plans that do not include
11	pharmacy benefits;
12	(vi) Other limited-benefit health insurance policies
13	<u>or plans;</u>
14	(vii) Health benefit plans provided under Arkansas
15	Constitution, Article 5, § 32, the Workers' Compensation Law, § 11-9-101 et
16	seq., and the Public Employee Workers' Compensation Act, § 21-5-601 et seq.;
17	<u>or</u>
18	(viii) A plan that provides only dental benefits or
19	eye and vision care benefits;
20	(4)(A) "Healthcare insurer" means an insurance company that is
21	subject to state law regulating insurance and offers health insurance
22	coverage under 42 U.S.C. § 300gg-91, as it existed on January 1, 2021, a
23	health maintenance organization, or a hospital and medical service
24	corporation.
25	(B) "Healthcare insurer" does not include an entity that
26	provides only dental benefits or eye and vision care benefits;
27	(5) "Healthcare service" means an item or service provided to an
28	individual for the purpose of preventing, alleviating, curing, or healing
29	illness, injury, or physical disability; and
30	(6) "Person" means a natural person, corporation, mutual
31	company, unincorporated association, partnership, joint venture, limited
32	liability company, trust, estate, foundation, not-for-profit corporation,
33	unincorporated organization, government, or governmental subdivision or
34	agency.
35	
36	23-79-2103. Fairness in cost sharing.

HB1569

1	(a)(1) When calculating an enrollee's contribution to any applicable
2	cost-sharing requirement, a healthcare insurer shall include any cost-sharing
3	amounts paid by the enrollee or on behalf of the enrollee by another person.
4	(2) The cost-sharing requirement under subdivision (a)(1) of
5	this section does not apply for cost-sharing of a prescription drug if a
6	name-brand prescription drug is prescribed and the prescribed drug:
7	(A) Is not considered to be medically necessary by the
8	prescriber; and
9	(B) Has a medically appropriate generic prescription drug
10	equivalent.
11	(b)(1) Except as provided in subdivision (b)(2) of this section, this
12	section applies to a health benefit plan that is entered into, amended,
13	extended, or renewed on or after January 1, 2022.
14	(2)(A) Benefits offered through a health benefit plan under the
15	Evidenced-Based Prescription Drug Program of the College of Pharmacy of the
16	University of Arkansas Medical Sciences shall satisfy the requirements of
17	this act beginning on and after January 1, 2024, if the Insurance
18	Commissioner reports a failure to comply with this section to the Legislative
19	<u>Council.</u>
20	(B)(i) Beginning on January 1, 2022, the Director of the
<u>.</u>	
21	Evidenced-Based Prescription Drug Program of the College of Pharmacy of the
21 22	Evidenced-Based Prescription Drug Program of the College of Pharmacy of the University of Arkansas Medical Sciences shall report quarterly to the
22	University of Arkansas Medical Sciences shall report quarterly to the
22 23	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council
22 23 24	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits
22 23 24 25	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits an enrollee and the offered plan.
22 23 24 25 26	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits an enrollee and the offered plan. (ii) The report described in subdivision
22 23 24 25 26 27	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits an enrollee and the offered plan. (ii) The report described in subdivision (b)(2)(B)(i) of this section shall include the amount of enrollee savings,
22 23 24 25 26 27 28	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits an enrollee and the offered plan. (ii) The report described in subdivision (b)(2)(B)(i) of this section shall include the amount of enrollee savings, plan-specific data on the amount of manufacturer rebates received, and how
22 23 24 25 26 27 28 29	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits an enrollee and the offered plan. (ii) The report described in subdivision (b)(2)(B)(i) of this section shall include the amount of enrollee savings, plan-specific data on the amount of manufacturer rebates received, and how the manufacturer rebates were applied in each plan for which the program is
22 23 24 25 26 27 28 29 30	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits an enrollee and the offered plan. (ii) The report described in subdivision (b)(2)(B)(i) of this section shall include the amount of enrollee savings, plan-specific data on the amount of manufacturer rebates received, and how the manufacturer rebates were applied in each plan for which the program is contracted to administer a prescription drug benefit.
22 23 24 25 26 27 28 29 30 31	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits an enrollee and the offered plan. (ii) The report described in subdivision (b)(2)(B)(i) of this section shall include the amount of enrollee savings, plan-specific data on the amount of manufacturer rebates received, and how the manufacturer rebates were applied in each plan for which the program is contracted to administer a prescription drug benefit. (c) The General Assembly intends for this section to regulate a
22 23 24 25 26 27 28 29 30 31 32	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits an enrollee and the offered plan. (ii) The report described in subdivision (b)(2)(B)(i) of this section shall include the amount of enrollee savings, plan-specific data on the amount of manufacturer rebates received, and how the manufacturer rebates were applied in each plan for which the program is contracted to administer a prescription drug benefit. (c) The General Assembly intends for this section to regulate a
22 23 24 25 26 27 28 29 30 31 32 33	University of Arkansas Medical Sciences shall report quarterly to the commissioner, Arkansas Legislative Audit, and the Legislative Council concerning details of plan savings and how the process that is used benefits an enrollee and the offered plan. (ii) The report described in subdivision (b)(2)(B)(i) of this section shall include the amount of enrollee savings, plan-specific data on the amount of manufacturer rebates received, and how the manufacturer rebates were applied in each plan for which the program is contracted to administer a prescription drug benefit. (c) The General Assembly intends for this section to regulate a healthcare insurer only to the extent permissible under applicable law.

1	(b) The rules promulgated under this section shall require a
2	healthcare insurer and the Director of the Evidenced-Based Prescription Drug
3	Program of the College of Pharmacy of the University of Arkansas Medical
4	Sciences to submit to the commissioner plan-specific information related to
5	savings and accountability to document how enrollees are realizing a cost
6	savings under each plan.
7	
8	SECTION 3. Arkansas Code Title 23, Chapter 92, Subchapter 5, is
9	amended to add an additional section to read as follows:
10	23-92-511. Fairness in cost sharing — Definitions.
11	(a) As used in this section:
12	(1) "Cost-sharing requirement" means a copayment, coinsurance,
13	deductible, or annual limitation on cost sharing, including without
14	limitation a limitation subject to the Patient Protection and Affordable Care
15	Act, Pub. L. No. 111-148, that is required by or on behalf of an enrollee in
16	order to receive a specific healthcare service, including a prescription
17	drug, covered by a health benefit plan;
18	(2) "Enrollee" means an individual entitled to healthcare
19	services from a healthcare insurer;
20	(3)(A) "Healthcare insurer" means an insurance company that is
21	subject to state law regulating insurance and offers health insurance
22	coverage under 42 U.S.C. § 300gg-91, as it existed on January 1, 2021, a
23	health maintenance organization, or a hospital and medical service
24	corporation.
25	(B) "Healthcare insurer" does not include an entity that
26	provides only dental benefits or eye and vision care benefits;
27	(4) "Healthcare service" means an item or service provided to an
28	individual for the purpose of preventing, alleviating, curing, or healing
29	human illness, injury, or physical disability; and
30	(5) "Person" means a natural person, corporation, mutual
31	company, unincorporated association, partnership, joint venture, limited
32	liability company, trust, estate, foundation, not-for-profit corporation,
33	unincorporated organization, government, or governmental subdivision or
34	agency.
35	(b)(1) When calculating an enrollee's contribution to any applicable
36	cost-sharing requirement, a healthcare insurer shall include any cost-sharing

03-15-2021 10:17:43 ANS138

1	amounts paid by the enrollee or on behalf of the enrollee by another person.
2	(2) The cost-sharing requirement under subdivision (b)(1) of
3	this section does not apply for cost-sharing of a prescription drug if a
4	name-brand prescription drug is prescribed and the prescribed drug:
5	(A) Is not considered to be medically necessary by the
6	prescriber; and
7	(B) Has a medically appropriate generic prescription drug equivalent.
8	(c)(l) Except as provided in subdivision (c)(2) of this section, this
9	section applies to a health benefit plan that is entered into, amended,
10	extended, or renewed on or after January 1, 2022.
11	(2)(A) Benefits offered through a health benefit plan under the
12	Evidenced-Based Prescription Drug Program of the College of Pharmacy of the
13	University of Arkansas Medical Sciences shall satisfy the requirements of
14	this act beginning on and after January 1, 2024, if the Insurance
15	Commissioner reports a failure to comply with this section to the Legislative
16	<u>Council.</u>
17	(B)(i) Beginning on January 1, 2022, the Director of the
18	Evidenced-Based Prescription Drug Program of the College of Pharmacy of the
19	University of Arkansas Medical Sciences shall report quarterly to the
20	commissioner, Arkansas Legislative Audit, and the Legislative Council
21	concerning details of plan savings and how the process that is used benefits
22	an enrollee and the offered plan.
23	(ii) The report described in subdivision
24	(c)(2)(B)(i) of this section shall include the amount of enrollee savings,
25	plan-specific data on the amount of manufacturer rebates received, and how
26	the manufacturer rebates were applied in each plan for which the program is
27	contracted to administer a prescription drug benefit.
28	(d)(l) The commissioner shall promulgate rules necessary to carry out
29	this section.
30	(2) The rules promulgated under this section shall require a
31	healthcare insurer and the director to submit plan-specific information
32	related to savings and accountability to document how enrollees are realizing
33	a cost savings under each plan.
34	(e) The General Assembly intends for this section to regulate a
35	healthcare insurer only to the extent permissible under applicable law.
36	

1	SECTION 4. TEMPORARY LANGUAGE. DO NOT CODIFY. Rules.
2	(a) The Insurance Commissioner shall promulgate rules necessary to
3	implement this act.
4	(b)(1) When adopting the initial rules to implement this act, the
5	final rule shall be filed with the Secretary of State for adoption under §
6	<u>25-15-204(f):</u>
7	(A) On or before January 1, 2022; or
8	(B) If approval under § 10-3-309 has not occurred by
9	January 1, 2022, as soon as practicable after approval under § 10-3-309.
10	(2) The commissioner shall file the proposed rule with the
11	Legislative Council under § 10-3-309(c) sufficiently in advance of January 1,
12	2022, so that the Legislative Council may consider the rule for approval
13	before January 1, 2022.
14	
15	/s/Lundstrum
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	